| Literature DB >> 32517237 |
Jih-Jung Chen1,2, Shih-Wei Wang3,4, Yin-Ru Chiang5, Ka-Lai Pang6, Yueh-Hsiung Kuo7,8,9, Tsai-Yen Shih10, Tzong-Huei Lee10.
Abstract
Agar-based disc diffusion antimicrobial assay has shown that the ethyl acetate extract of the fermented broth of Aspergillus giganteus NTU967 isolated from Ulva lactuca exhibited significant antimicrobial activity in our preliminary screening of bioactive fungal strains. Therefore, column chromatography of the active principles from liquid- and solid-state fermented products of the fungal strain was carried out, and which had led to isolation of eleven compounds. Their structures were determined by spectral analysis to be seven new highly oxygenated polyketides, namely aspergilsmins A-G (1-7), along with previously reported patulin, deoxytryptoquivaline, tryptoquivaline and quinadoline B. Among these, aspergilsmin C (3) and patulin displayed promising anticancer activities against human hepatocellular carcinoma SK-Hep-1 cells and prostate cancer PC-3 cells with IC50 values between 2.7-7.3 μM. Furthermore, aspergilsmin C (3) and patulin exhibited significant anti-angiogenic functions by impeding cell growth and tube formation of human endothelial progenitor cells without any cytotoxicity.Entities:
Keywords: Aspergillus giganteus; Polyketides; Trichocomaceae; aspergilsmin; bioactive natural products
Mesh:
Substances:
Year: 2020 PMID: 32517237 PMCID: PMC7374281 DOI: 10.3390/md18060303
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Chemical structures of compounds 1–7 and patulin.
13C NMR spectroscopic data for compounds 1–7 (δ in ppm, mult.).
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| 1 | 172.9 s | 173.6 s | 170.6 s | 170.6 s | 169.6 s | 170.6 s | 170.6 s |
| 2 | 36.7 t | 31.1 t | 111.9 d | 111.1 d | 119.7 d | 117.1 d | 119.9 d |
| 3 | 69.7 d | 111.7 s | 147.5 s | 147.6 s | 156.5 s | 163.9 s | 160.9 s |
| 4 | 191.8 s | 191.3 s | 150.9 s | 151.3 s | 148.2 s | 107.6 s | 107.2 s |
| 5 | 116.2 s | 77.3 d | 109.3 d | 109.4 d | 115.3 d | 40.3 t | 41.9 t |
| 6 | 166.1 d | 72.3 t | 60.0 t | 60.0 t | 57.3 t | 62.3 t | 58.3 t |
| 7 | 75.9 t | 164.0 d | 95.9 d | 94.8 d | 97.6 d | 98.8 d | 97.4 d |
| 8 | 57.7 q | 58.7 q | 56.5 q | 65.6 t | 62.8 t | 57.3 q | 55.5 q |
| 9 | 52.7 q | 52.5 q | 15.4 q | 15.4 q | 51.2 q | 52.2 q | |
| 10 | 53.2 q |
Measured in CD3OD (125 MHz); Multiplicties were obtained from phase-sensitive HSQC experiments.
1H NMR spectroscopic data for compounds 1–7 (δ in ppm, mult., J in Hz).
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| 1 | |||||||
| 2 | 2.61 d (6.2) | 3.14 s | 6.60 s | 6.05 s | 6.31 s | 6.12 s | 6.23 s |
| 3 | 4.55 | ||||||
| 4 | |||||||
| 5 | 3.70 t (4.7) | 6.02 m | 6.02 m | 5.85 t (6.9) | 1.91 m | 1.99 m | |
| 2.38 dt (13.5, 2.1) | 2.34 d (13.2) | ||||||
| 6 | 7.66 s | 4.49 d (4.7) | 4.37 dd (17.5, 4.4) | 4.36 dd (17.3, 4.4) | 4.40 d (6.9) | 3.76 td (12.2, 2.1) | 3.71 m |
| 4.56 dd (17.5, 2.5) | 4.56 dd (17.3, 2.6) | 4.01 m | 4.10 td (12.0, 2.0) | ||||
| 7 | 4.55 | 7.50 s | 5.68 s | 5.79 s | 5.52 s | 5.11 s | 5.52 s |
| 8 | 3.35 s | 3.45 s | 3.54 s | 3.71 m | 3.63 m | 3.60 s | 3.46 s |
| 3.91 m | |||||||
| 9 | 3.71 s | 3.67 s | 1.26 t (7.1) | 1.24 t (7.1) | 3.23 s | 3.19 s | |
| 10 | 3.36 s |
Measured in CD3OD (400 MHz); Measured in CD3OD (500 MHz); c Signals were overlapped and were picked up from HSQC spectrum.
Figure 2COSY and key HMBC and ROESY correlations of compounds 1, 2, 5, 6 and 7.
Anticancer and anti-angiogenic activities of compound 3 and patulin.
| Compounds | Anticancer (IC50, μM) | Anti-Angiogenesis (IC50, μM) | |
|---|---|---|---|
| SK-Hep-1 | PC-3 | EPC | |
| Compound | 2.7 ± 0.2 | 7.3 ± 0.3 | 4.6 ± 0.3 |
| Patulin | 2.9 ± 0.1 | 2.7 ± 0.1 | 4.7 ± 0.2 |
| Paclitaxel | 0.011 ± 0.002 | 0.013 ± 0.002 | – |
| Sorafenib | – | – | 4.8 ± 0.3 |
Hepatocellular carcinoma cells; Prostate cancer cells; Endothelial progenitor cells; Positive control.
Figure 3Effects of compound 3 and patulin on tube formation and cytotoxicity of human EPCs. (A) EPCs were treated with compound 3, patulin and sorafenib (10 μM) for 24 h. Tubular morphogenesis was recorded by the inverted phase contrast microscope. Representative images of EPCs’ tube formation were shown; (B) tube formation was quantified by measuring the length of tubes using ImageJ software; (C) Cells were treated with the indicated compounds for 24 h, then the cytotoxicity was determined using LDH assay Data represent the mean ± S.E.M. of 4 independent experiments. * p < 0.05 compared with the control group.